Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: iGenix, Illumina; Sigma-Aldrich; Becton Dickinson; UK's National Cancer Research Institute; SRU Biosystems

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Seattle-based iGenix has been named an Illumina certified service provider for the BeadXpress platform. iGenix said that it specializes in biomarker evaluation and helps clients develop new diagnostic assays for the BeadXpress platform.


Sigma-Aldrich said this week that its board of directors has declared a quarterly cash dividend of $.16 per share to be payable on Dec. 15 to shareholders of record on Dec. 1.


Becton Dickinson sold $1 billion worth of senior notes this past week. The firm sold $700 million of 3.25 percent notes due Nov. 12, 2020, and $300 million of 5 percent notes due Nov. 12, 2040.


The UK's National Cancer Research Institute has launched the UK Prostate Cancer Sample Collection Database. NCRI said that in addition to 10,000 biological samples taken from men in the UK with and without prostate cancer, the biobank will also hold other materials for research, including DNA, RNA, blood, and urine. The biobank will hold both clinical and molecular data.


SRU Biosystems is offering its newest label-free BIND Scanner to an academic or non-profit lab that wins its annual Label-free Technology Award. The Woburn, Mass.-based firm said the recipient of the award will be chosen based on "scientific merit, novelty of research, and the promise of advancing science and medicine using label-free technology.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.